Our analysis suggests that TGFB2’s mode of action is independent of the tumor’s IDHwt genotype, even though the IDHwt genotype is also independently negatively prognostic; it involves the co-activation of IFNGR2 pathways, eliciting downstream signaling molecules IFNGR2, IRF1, IRF5, and STAT1; CD276-positive tumor cells; and TAMs to impact OS. This evidence concerns the gene IRF5 and neoplasm.